<?xml version='1.0' encoding='utf-8'?>
<document id="27836670"><sentence text="In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation."><entity charOffset="74-83" id="DDI-PubMed.27836670.s1.e0" text="bupropion" /></sentence><sentence text="Bupropion is a widely used antidepressant and smoking cessation aid and a strong inhibitor of CYP2D6 in vivo"><entity charOffset="0-9" id="DDI-PubMed.27836670.s2.e0" text="Bupropion" /></sentence><sentence text=" Bupropion is administered as a racemic mixture of R- and S-bupropion and has stereoselective pharmacokinetics"><entity charOffset="1-10" id="DDI-PubMed.27836670.s3.e0" text="Bupropion" /></sentence><sentence text=" Four primary metabolites of bupropion, threo- and erythro-hydrobupropion and R,R- and S,S-OH-bupropion, circulate at higher concentrations than the parent drug and are believed to contribute to the efficacy and side effects of bupropion as well as to the CYP2D6 inhibition"><entity charOffset="29-38" id="DDI-PubMed.27836670.s4.e0" text="bupropion" /><entity charOffset="228-237" id="DDI-PubMed.27836670.s4.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.27836670.s4.e0" e2="DDI-PubMed.27836670.s4.e0" /><pair ddi="false" e1="DDI-PubMed.27836670.s4.e0" e2="DDI-PubMed.27836670.s4.e1" /></sentence><sentence text=" However, bupropion and its metabolites are only weak inhibitors of CYP2D6 in vitro, and the magnitude of the in vivo drug-drug interactions (DDI) caused by bupropion cannot be explained by the in vitro data even when CYP2D6 inhibition by the metabolites is accounted for"><entity charOffset="10-19" id="DDI-PubMed.27836670.s5.e0" text="bupropion" /><entity charOffset="157-166" id="DDI-PubMed.27836670.s5.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.27836670.s5.e0" e2="DDI-PubMed.27836670.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27836670.s5.e0" e2="DDI-PubMed.27836670.s5.e1" /></sentence><sentence text=" The aim of this study was to quantitatively explain the in vivo CYP2D6 DDI magnitude by in vitro DDI data" /><sentence text=" Bupropion and its metabolites were found to inhibit CYP2D6 stereoselectively with up to 10-fold difference in inhibition potency between enantiomers"><entity charOffset="1-10" id="DDI-PubMed.27836670.s7.e0" text="Bupropion" /></sentence><sentence text=" However, the reversible inhibition or active uptake into hepatocytes did not explain the in vivo DDIs" /><sentence text=" In HepG2 cells and in plated human hepatocytes bupropion and its metabolites were found to significantly downregulate CYP2D6 mRNA in a concentration dependent manner"><entity charOffset="48-57" id="DDI-PubMed.27836670.s9.e0" text="bupropion" /></sentence><sentence text=" The in vivo DDI was quantitatively predicted by significant down-regulation of CYP2D6 mRNA and reversible inhibition of CYP2D6 by bupropion and its metabolites"><entity charOffset="131-140" id="DDI-PubMed.27836670.s10.e0" text="bupropion" /></sentence><sentence text=" This study is the first example of a clinical DDI resulting from CYP down-regulation and first demonstration of a CYP2D6 interaction resulting from transcriptional regulation" /><sentence text="" /></document>